Financial & Business News

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.

HAUPPAUGE, N.Y., June 26, 2025 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (Nasdaq: DCOM) (the “Company”) announced that its Board of Directors declared a quarterly cash dividend of $0.25 per share of Common Stock, payable on July 24, 2025 to common stockholders of record as of July 17, 2025.

Third Quarter of Fiscal 2025 Continuing Operations Highlights * Net sales were $159 million, a 5.5% increase compared to the prior year, with a 2.0% increase in organic sales.1 Operating profit margin was 20.0% and adjusted operating profit margin was 24.1%. Net earnings were $22.0 million, or $0.41 per diluted share.

HOUSTON--(BUSINESS WIRE)--WM (NYSE: WM) announced that it will release second quarter financial results after the close of the market on Monday, July 28, 2025, and host its investor conference call on Tuesday, July 29 at 10 a.m. ET. Listeners can access a live audio webcast of the conference call by visiting investors.wm.com and selecting “Events & Presentations” from the website menu. A replay of the audio webcast will be available at the same location following the conclusion of the call.

LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the submission of a Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of its lead pipeline program AX-0810 targeting NTCP, a liver cell protein that transports bile acids into cells. AX-0810 is an investigational ADAR-mediated RNA editing oligonucleotide (EON) designed to selectively modulate NTCP function by reducing toxic bile acid accumulation in the liver, potentially mitigating inflammation, fibrosis, and progression toward liver failure, which are common in cholestatic diseases.

ATHENS, Greece, June 26, 2025 (GLOBE NEWSWIRE) -- TOP Ships Inc. (the “Company” or “TOP Ships”) (NYSE American: TOPS), an international owner and operator of modern, fuel-efficient “ECO” tanker vessels, announced today that the application of Rubico Inc. (“Rubico”), to list its common shares on the Nasdaq Capital Market has been approved. In addition, the registration statement on Form 20-F filed by Rubico in connection with its spin-off from Top Ships Inc has been declared effective by the U.S. Securities and Exchange Commission (the “SEC”).

ORLANDO, Fla.--(BUSINESS WIRE)--Travel + Leisure Co. (NYSE:TNL) announced today it will release second quarter 2025 financial results on Wednesday, July 23, 2025, before the market opens, followed by a conference call at 8:00 a.m. EDT. Michael D. Brown, President and CEO, and Erik Hoag, CFO, will discuss the Company's business outlook and financial performance. Participants may listen to a simultaneous webcast of the conference call, which may be accessed through the Company's website at travel.

HOUSTON--(BUSINESS WIRE)--DNOW Inc. (NYSE: DNOW) (“DNOW” or “the Company”) and MRC Global Inc. (NYSE: MRC) (“MRC Global”) today announced that they have entered into a definitive merger agreement pursuant to which DNOW will acquire MRC Global in an all-stock transaction valued at approximately $1.5 billion, inclusive of MRC Global's net debt, creating a premier energy and industrial solutions provider. The combination brings together two global energy and industrial infrastructure organizations.

PhenixFIN's internalized management and aggressive buybacks have driven strong NAV growth, and significant insider alignment sets a solid foundation for value creation. The ECC Capital transaction unlocks a hidden asset: a massive deferred tax asset at ECRO, potentially offering substantial upside not reflected in current book value. PFX's concentrated portfolio, equity-heavy approach, and limited liquidity pose risks, but also differentiate it from traditional BDCs and create tracking opportunities.

CNBC's Tanaya Macheel reports on news regarding Circle.